About half of U.S. adults have high blood pressure and too few have it under control. Now some patients who've tried ...

Piper Sandler adjusted its outlook on Keros Therapeutics (NASDAQ:KROS), significantly reducing the price target from $40.00 ...

Whether you’re a senior in high school or a senior-living resident, you’ve likely heard of Viagra (sildenafil) — the original ...

Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the ...

Keros Therapeutics said on Wednesday it would voluntarily halt testing of an experimental blood pressure treatment due to safety concerns during a mid-stage trial, causing its shares to hit a record ...

A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension ...

Keros Therapeutics has halted the dosing of its treatment for pulmonary hypertension due to adverse health effects discovered during trials. The clinical-stage biopharmaceutical company said Wednesday ...

Keros Therapeutics (KROS) announced that it has voluntarily halted all dosing in the TROPOS trial, a Phase 2 clinical trial of cibotercept in ...

Erri, S. and Oroszi, T. (2025) Isolated Systolic Hypertension in Geriatrics. International Journal of Clinical Medicine, 16, ...

A body weight-adjusted regimen of Uptravi dosing for children and adolescents with PAH was deemed appropriate, according to a ...

VIVUS will be discussing its significant 2024 momentum during the J.P. Morgan Healthcare Conference, with an emphasis on what we as a company aim to achieve during the coming months around our novel ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ALG-801, Alivegen ’s experimental ...